Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRK-750 for oxaliplatin-induced peripheral neuropathy in colorectal cancer
2019-003561-17Phase 2Unknown
- Sponsor
- Toray Industries
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of TRK-750 in chemotherapy-induced peripheral neuropathy (CIPN), sponsored by Toray Industries. Primary endpoint: Safety and tolerability. Status: unknown.
02
Drugs
TRK-750
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on 2019-003561-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003561-17.